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Abstract
Introduction—In 2012, ACIP recommended 13-valent pneumococcal conjugate vaccine 
(PCV13) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) for adults ≥19 
at risk, and, in 2014, expanded this recommendation to adults ≥65. Primary care physicians’ 
practice, knowledge, attitudes and beliefs regarding these recommendations are unknown.
Methods—General internists (GIM) and family physicians (FP) throughout the U.S. were 
surveyed by email and mail from December 2015 to January 2016. Multivariable analysis 
examined characteristics associated with knowledge of the recommendations (January 2016-
September 2016).
Results—Response rate was 66% (617/935). Over 95% reported routinely assessing adults’ 
vaccination status and recommending both vaccines. A majority found the current 
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recommendations to be clear (50% ‘very clear’, 38% ‘somewhat clear’). Twenty percent found the 
upfront cost of purchasing PCV13, lack of insurance coverage, inadequate reimbursement and 
difficulty determining vaccination history to be ‘major barriers’ to giving these vaccines in series. 
Knowledge of recommendations was variable with 83% identifying the PCV13 recommendation 
for adults ≥65 and only 21% identifying the recommended interval between PCV13 and PPSV23 
in an individual <65 at increased risk. Characteristics associated with greater knowledge included 
GIM vs. FP specialty (adjusted RR=1.45; 95% CI 1.09–1.88), younger vs. older age (adjusted 
RR=1.41; 95% CI 1.04–1.88), and perceiving the recommendations to be ‘very clear’ vs. other 
perceptions (adjusted RR=1.50; 95% CI=1.15–1.96).
Conclusions—Almost all surveyed physicians reported recommending both pneumococcal 
vaccines, but there appears to be a disconnect between perceived clarity and knowledge of the 
recommendations. Optimal implementation of these recommendations will require addressing 
knowledge gaps and reported barriers.
Introduction
In the U.S., Streptococcus pneumoniae bacteria cause an estimated 445,000 hospitalizations 
annually1 and, in 2014, caused approximately 29,100 cases of invasive pneumococcal 
disease (IPD) and 3,250 deaths.2 Adult pneumococcal disease is the major source of 
pneumococcal disease-related healthcare utilization and costs.1
Vaccines are an effective way to prevent pneumococcal disease and thereby reduce the 
burden and cost of pneumococcal disease. In the U.S., the 23-valent pneumococcal 
polysaccharide vaccine (PPSV23) has been recommended for adults ≥ 65 and adults with 
high-risk conditions since 1984.4 These recommendations have been revised,5–7 expanding 
indications for the vaccination and introducing revaccination for some high-risk groups and 
for adults ≥ 65 who received their first dose of PPSV23 before age 65, but PPSV23 
remained the only available product for pneumococcal disease prevention among adults 
through 2011.
In 2011, pneumococcal conjugate vaccine (PCV13) was approved by the FDA for use 
among adults ≥50.8 The following year, ACIP recommended PCV13 in a series with 
PPSV23 for high-risk adults ≥19.9 In 2014, based on data demonstrating vaccine-
preventable disease burden and on results of the CAPITA trial10 showing efficacy of PCV13 
at preventing non-bacteremic pneumonia and invasive pneumococcal disease caused by 
vaccine serotypes in adults ≥ 65, ACIP expanded recommendations for the use of PCV13 to 
include recommending PCV13 in series with PPSV23 for all adults ≥65 years.11 In June 
2015, ACIP revised the recommended intervals between PCV13 and PPSV23 for adults ≥ 65 
from 6 months to 1 year.12
Despite longstanding ACIP recommendations for PPSV23 in adults, recent vaccination 
coverage among adults ≥ 65 years was 61% and among high-risk adults 19–64 was only 
20%,13 both well below Healthy People 2020 goals. Physician perception of these changes 
to the adult pneumococcal vaccine recommendations is unknown. Since physician 
recommendation is so important to patients’ receipt of vaccines,14–18 we sought to describe 
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current practice, knowledge, attitudes and beliefs of family physicians (FP) and general 
internists (GIM) regarding the current adult pneumococcal vaccine recommendations.
Methods
Study Setting
From December 2015 to January 2016, we administered a survey to a national network of 
physicians who spent at least half their time practicing primary care. The human subjects 
review board at the University of Colorado Denver approved this study as exempt research 
not requiring written informed consent.
Study Population
The Vaccine Policy Collaborative Initiative19, a survey mechanism to assess physician 
attitudes about vaccine issues, in collaboration with the Centers for Disease Control and 
Prevention (CDC), conducted the survey. We developed a network of primary care 
physicians by recruiting general internists (GIM) and family physicians (FP) from the 
memberships of the American College of Physicians (ACP) and the American Academy of 
Family Physicians (AAFP). We performed quota sampling20 to ensure that networks of 
physicians were similar to the ACP and AAFP memberships with respect to region, urban 
versus rural location, and practice setting. We previously demonstrated that survey responses 
from network physicians compared to those of physicians randomly sampled from American 
Medical Association physician databases were similar with respect to reported demographic 
characteristics, practice attributes, and attitudes about vaccination issues.20
Survey Design
We developed the survey collaboratively with CDC. The survey asked about physician 
practices regarding assessing need for, recommending, and stocking PCV13 and PPSV23 
vaccines and whether physicians referred patients out for either vaccine if the vaccine(s) 
were not stocked. We used 4-point Likert scales for assessing physician perception of the 
clarity of (‘Very clear’ to ‘Very Unclear’), ease of implementation of (‘Very easy’ to ‘Very 
difficult’) and barriers to following (‘Not a barrier’ to ‘Major Barrier’) the 2015 ACIP adult 
pneumococcal vaccine recommendations. Physicians were asked what type of resources 
would help clarify the recommendations and whether they had a computerized way to 
identify adults <65 who needed either pneumococcal vaccine. Physicians were presented a 
series of case scenarios and asked questions aimed to assess knowledge of specific elements 
of ACIP adult pneumococcal vaccine recommendations (Appendix Table 1). To encourage 
them to answer these questions without referring to other sources, ‘I would need to look this 
up’ was one available response option. A national advisory panel of GIM (n=6) and FP 
(n=7) pre-tested the survey, which we modified based on their feedback. We pilot-tested the 
survey among 50 GIM and 23 FP nationally and further modified based on their feedback.
Survey Administration
Based on physician preference, we sent the survey over the Internet21 or through U.S. mail. 
We sent the Internet group an initial e-mail with up to 8 e-mail reminders, and we sent the 
mail group an initial mailing and up to 2 additional reminders. Non-respondents in the 
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Internet group were also sent up to 2 mail surveys in case of problems with e-mail 
correspondence. We patterned the mail protocol on Dillman’s Tailored Design Method.22
Statistical analysis
Analyses were conducted January 2016 through September 2016. We pooled Internet and 
mail surveys for analyses because other studies have found that physician attitudes are 
similar when obtained by either method.14,22,23 We compared respondents with non-
respondents on all available characteristics using t-test and Mantel-Haenszel chi-square 
analyses; characteristics of non-respondents were obtained from the recruitment survey for 
the sentinel networks. We compared GIM and FP responses using Mantel-Haenszel and 
Pearson’s chi-square tests. Results were very similar for GIM and FP physicians, and, are 
therefore, presented together with any differences highlighted in the text. After excluding 
physicians who responded that they were not familiar with the recommendations (n=5), we 
used chi-square analysis to compare physicians who perceived the recommendations as 
‘very clear’ or ‘somewhat clear’ versus those who perceived them as ‘somewhat unclear’ or 
‘very unclear’ in terms what resources they reported would help clarify the 
recommendations. Multivariable analysis was conducted with the dependent variable being 
respondents who answered six to eight out of eight knowledge questions (the top quartile of 
respondents) pertaining to current ACIP adult pneumococcal vaccine recommendations 
correctly. Independent variables included physician characteristics and practice 
characteristics and whether the practice had a computer-based way to identify patients <65 
who need either PCV13 and/or PPSV23. Characteristics significant at p ≤ 0.25 in bivariate 
analyses were tested in multivariable models using backwards elimination resulting in 
retention of only those factors that were significant at p<0.05 in the final model. Risk ratios 
were calculated because of the tendency of odds ratios to overestimate effect sizes when 
outcomes are common. Calculation of adjusted risk ratios was conducted using log-binomial 
models (SAS PROC GENMOD ). All analyses were performed using SAS, version 9.4 
(SAS Institute, Cary, North Carolina).
Results
Survey response and characteristics of respondents
Response rates were 68% for GIM (324/480) and 64% for FP (293/455). Respondents and 
non-respondents did not differ significantly by census location (urban, suburban or rural). 
Among GIM physicians, older physicians and physicians working in private and smaller 
practices were less likely to respond (p=<0.01). Among FP, male physicians and physicians 
from the South were less likely to respond and physicians from the Midwest were more 
likely respond (p≤0.05). Characteristics of respondents and non-respondents and further 
characteristics of respondents’ practices and patient populations are shown in Table 1. Of 
those who responded, 15 (7 GIM and 8 FP) reported they do not give immunizations to adult 
patients and were excluded from further analysis leaving a final cohort of 602 (317 GIM, 
285 FP).
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Current Pneumococcal Vaccination Practices
Nearly all respondents reported assessing need for (96%) and recommending (95%) PCV13; 
86% reported stocking it. Almost all respondents reported assessing need for (98%) and 
recommending (97%) PPSV23; 92% reported stocking it. Thirty-one and 38% reported 
having a computer-based way to identify adults <65 who needed PCV13 or PPSV23, 
respectively. Of those physicians who reported not stocking PCV13 (n=72) or PPSV23 
(n=49), 81% and 72%, correspondingly, referred patients elsewhere for the vaccine.
Perceptions of ACIP Adult Pneumococcal Vaccine Recommendations
The majority of respondents reported that the recommendations were clear (50% ‘very clear’ 
and 38% ‘somewhat clear’); 11% reported that they are ‘somewhat’ or ‘very’ unclear, and 
1% said they weren’t familiar with the recommendations. Most also reported the 
recommendations were easy to implement in practice (48% ‘very easy,’ 34% ‘somewhat 
easy’); 17% reported it was ‘somewhat’ or ‘very difficult’ to implement the 
recommendations. Physicians reported the following resources would help clarify the 
recommendations: a simplified fact sheet/flow diagram with patient scenarios (82%), an 
electronic medical record prompt (81%), an on-line self-paced continuing medical education 
course (56%), an interactive, patient-specific mobile app (45%), or an online webinar (36%). 
We found no statistical difference in responses to what resources would help clarify the 
recommendations between physicians who perceived the recommendations as clear versus 
those who perceived them as unclear. Figure 1 shows the perceived barriers to giving PCV13 
and PPSV23 in series.
Knowledge of ACIP’s Adult Pneumococcal Vaccine Recommendations
Table 2 shows results of a series of case-based questions evaluating respondent knowledge 
of ACIP’s adult pneumococcal vaccine recommendations. We identified variability in the 
proportion of correct responses. Physicians were most knowledgeable about which 
pneumococcal vaccine to give first to adults ≥ 65 and least knowledgeable about the 
recommended interval between PCV13 and PPSV23 vaccines in patients <65 at high-risk, 
often providing the correct response for the interval recommended for adults ≥ 65 (54%). 
Despite being given the option to say they would need to look the answer up, approximately 
a third or more of physicians answered half of the questions incorrectly.
Physician Characteristics Associated with Knowledge of ACIP’s Adult Pneumococcal 
Vaccine Recommendations
As shown in Table 3, FP specialty and increasing age were significantly associated with 
lower knowledge scores regarding the recommendations, whereas physician perception of 
the recommendations as ‘very clear’ was associated with higher knowledge scores. Having 
an automated, computer-based way to identify patients <65 years who needed PCV13 or 
PPSV23 was not predictive of higher scores.
Discussion
Almost all physicians reported assessing the need for, recommending and stocking both 
pneumococcal vaccines, and, if they did not stock pneumococcal vaccines, referring patients 
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to receive them elsewhere. While most physicians reported the recommendations were clear, 
several knowledge gaps regarding the recommendations were identified. Physicians reported 
electronic medical prompts would help clarify the recommendations, and the majority 
reported not having them in place. The top reported barriers to giving pneumococcal 
vaccines in series were financial concerns and difficulty determining a patient’s 
pneumococcal vaccination history.
In previous surveys, physicians have reported financial barriers to providing adult vaccines,
24,25
 primarily that they are inadequately reimbursed.26 The specific reported barriers in this 
study about Medicare not covering the pneumococcal vaccines in series and insurance not 
paying for pneumococcal vaccines if the appropriate time had not elapsed may be rooted in 
initial disparities between Medicare policy and the recommendations. ACIP recommended 
both pneumococcal vaccines to be given in series to adults ≥ 65 in August 2014, and while 
the Centers for Medicare and Medicaid (CMS) responded swiftly to change regulations to 
allow series’ coverage in February 2015, there were months where the recommendations and 
Medicare policy were not aligned. Also, even though ACIP initially recommended different 
intervals between the two pneumococcal vaccines depending on which was given first, CMS 
would only pay for both vaccines if a year elapsed between the administration of the two 
vaccines, regardless of which vaccine had been given first. ACIP subsequently re-evaluated 
their adult pneumococcal recommendations, and, in September 2015 recommended a year 
interval between the vaccines regardless of which vaccine was given first. The main reason 
for this change was to simplify the recommendation because the evidence supported the 
longer interval for immunocompetent adults, but part of the rationale was to coordinate 
ACIP recommendations with Medicare payment. Both vaccines are covered under Medicare 
Part B and over 90% of Medicare beneficiaries have Medicare Part B.27 The fact that 
physicians are still reporting these barriers to giving pneumococcal vaccines in series in 
2016 suggests a need to evaluate why physicians perceive this and to investigate how to 
better communicate policy changes.28,29
Physicians also reported private insurance and Medicaid not covering pneumococcal 
vaccines being barriers to giving these vaccines in series. Most private insurance companies 
should be covering these vaccines since the Affordable Care Act mandates that ACIP 
recommended vaccines be covered with no cost-share in non-grandfathered insurance plans. 
The perception that these vaccines are not covered by private insurance may have a couple 
of explanations. Since pneumococcal vaccine recommendations for high-risk adults under 
65 and for adults ≥ 65 are relatively new, there may have been a lag between ACIP making 
these recommendations and private insurance companies covering them. Also, some private 
insurance plans are “grand-fathered” and do not have to adhere to the Affordable Care Act 
(ACA) mandate that all ACIP recommended vaccines be covered; 23% of employer-based 
insurance met this criteria in 2016.30 State Medicaid agencies cover PPSV23 variably for 
adults and this might partially explain several physicians reporting that Medicaid does not 
cover these vaccines in series. Medicaid provider reimbursement for adult immunizations in 
201231 found that at least three state Medicaid agencies did not cover the PPSV23; state 
Medicaid coverage of PCV13 is not published, but may be presumably lower given how 
much more expensive PCV13 is compared to PPSV23.32 The ACA did not affect 
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physicians’ vaccine purchasing costs so unsurprisingly physicians found up-front costs of 
purchasing pneumococcal vaccines to be a deterrent to giving these vaccines in series.
Aside from financial barriers, the most common barrier was difficulty determining 
vaccination history; a similar finding to a general internist’s survey concerning PPSV23.33 
Giving unnecessary vaccines leads to unwarranted expense, denial of insurance claims, and, 
although the risk of severe adverse events from PCV13 and PPSV23 is low, it also exposes 
patients to potential vaccine-related adverse events. Adults may receive pneumococcal 
vaccines at various locations including primary care physicians’ and subspecialists’ offices 
and retail pharmacies. Pharmacies in all states have jurisdiction to administer pneumococcal 
vaccine to adults.34 Adults also move around and do not necessarily keep good vaccination 
records. These factors combine to complicate determining patients’ pneumococcal 
vaccination history. Immunization information systems (IISs) are confidential, computerized 
systems that collect and consolidate vaccination data from multiple vaccine providers and 
broad use of IISs could partially address this identified barrier.35,36 Although the National 
Vaccine Advisory Committee standards and Community Preventive Services Task Force 
Guideline encourage IIS use,37 72% of family physicians, but only 27% of general internists 
are using them.38
While physicians did not generally report ignorance about pneumococcal vaccines was a 
major barrier to giving these vaccines in series, their responses to knowledge questions tell a 
different story. Physicians were most knowledgeable about the recommendation to give 
PCV13 first to adults ≥ 65. This is possibly related to age-based recommendations being 
easier to understand and/or media campaigns specifically targeting seniors. Physicians were 
less knowledgeable about other adult PCV13 recommendations and this is possibly 
attributable to the newness of the recommendations and complexity of the risk-based 
recommendations. The confusion about the timing between PCV13 and PPSV23 in adults ≥ 
65 may be due to the recommendation changes that occurred in a brief interval11,12 
Physicians were least knowledgeable about the recommended interval between PCV13 and 
PPSV23 for high-risk adults <65, yet often gave the correct response for adults ≥ 65, 
suggesting a lack of recognition of the differences in the recommendations for these two 
populations. Knowledge gaps were not limited to the new pneumococcal vaccine 
recommendations. Physicians were also confused about asthma being a qualifying condition 
for PPSV23 and the timing between PPSV23 doses for high-risk <65 and for adults ≥ 65 
when the first dose of PPSV23 was received before age 65. PPSV23 has been recommended 
for patients with asthma since 20107 and the recommended revaccination intervals between 
doses of PPSV23 have not been changed since 1997.6
Another notable issue with the knowledge questions is that large percentages of physicians 
(11–58%) still answered questions incorrectly despite being offered the response option of 
needing to look the answer up. This may indicate they feel confident in their incorrect 
answers and would not use resources that would need to be sought out to guide their 
decisions.39 This has implications on optimal vaccine delivery and possibly contributes to 
the low adult coverage rates for pneumococcal vaccines that have been observed.13 Family 
physicians and older physicians were less knowledgeable about the recommendations. 
Family physicians may tend to see younger patients than general internists40 (Table 1) and 
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fewer patients with chronic medical conditions40 which might explain these findings. Since 
there have been several pneumococcal vaccine recommendation iterations, older physicians 
may be more familiar with earlier versions.
The confusion identified suggests having an active clinical decision support system (CDSS) 
to identify adult patients needing pneumococcal vaccines at a visit, and not relying on 
physician knowledge, could help pneumococcal vaccine recommendation implementation. 
Electronic Health Record (EHR) technology makes CDSSs possible. Over ninety percent of 
physicians reported using an EHR, but only approximately a third indicated having a 
computerized way to identify high-risk patients needing either pneumococcal vaccines. 
However, the majority (81%) indicated electronic medical prompts would help clarify the 
recommendations. Due to the challenge of interpreting clinically-written ACIP 
recommendations, current CDSS engine outputs often vary and are inconsistent in accurately 
reflecting ACIP recommendations.41 The CDC created and continues to work on CDSS 
resources that can be integrated into EHRs that capture ACIP recommendations and could 
prove useful to adult pneumococcal vaccination efforts.41
Our study has strengths and limitations. Results were generated from primary care 
physicians from across the nation and we achieved an excellent response rate for a physician 
survey.42,43 Although our sample was designed to be representative of ACP and AAFP 
memberships, the attitudes, experiences, and practices of sentinel physicians may not be 
fully generalizable. Non-respondents may have held different views than respondents. The 
survey relied on self-report of practice rather than observation of practice.
Primary care physicians’ reported stocking and recommending pneumococcal vaccine 
practices suggest a positive outlook for implementation of ACIP recommendations. 
However, realizing optimal implementation will require ensuring coverage for these 
vaccines, physician awareness of this coverage, and addressing knowledge gaps regarding 
these recommendations. Our data support harnessing EHR capability to create accurate 
CDSSs for these complex recommendations that would actively prompt physicians to 
accurately apply ACIP pneumococcal recommendations as opposed to looking up 
information they think they know.
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Figure 1. Barriers to Following ACIP Recommendations for giving PCV13 and PPSV23 in series
*FP significantly more likely than GIM to report this barrier, p<0.05
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Table 1
Respondent and Non-Respondent Characteristics
Characteristic GIM FP
Respondents(n=324) Non-Respondents (n=156) Respondents (n=293) Non-Respondents (n=162)
Age in years, mean (SD)† 52.9 (9.2) 55.8 (8.2) 54.3 (7.8) 54.8 (8.3)
Male, %* 56 62 52 64
Region, %*
 Midwest 22 21 32 22
 Northeast 24 24 12 16
 South 30 37 33 43
 West 24 18 23 19
Location of Practice, %
 Urban 56 53 37 37
 Suburban 43 46 54 54
 Rural 1 2 9 9
Setting, %†
 Private practice 75 87 68 71
 Hospital/clinic 21 11 23 18
 HMO 4 2 9 11
# of providers in your practice, %†
 1 13 25 12 13
 2–4 25 24 26 31
 5–10 28 27 37 34
 ≥10 34 25 26 22
Physicians providing 
vaccines to adults, % 98 N/A 97 N/A
Practice uses an EMR/EHR, 
%
94 N/A 93 N/A
Proportion of patients ≥ 65,%
 <10% 3 N/A 7 N/A
 10–24% 10 N/A 25 N/A
 25–49% 34 N/A 44 N/A
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Characteristic GIM FP
Respondents(n=324) Non-Respondents (n=156) Respondents (n=293) Non-Respondents (n=162)
 ≥50% 53 N/A 23 N/A
Practice accepts Medicare, 
%
94 N/A 96 N/A
Practice accepts Medicaid, % 64 N/A 80 N/A
*p<0.05 for comparison of respondents and non-respondents within FP
†p<0.05 for comparison of respondents and non-respondents within GIM
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